The 2022 Sustainability Report has been published.

The 2022 Annual Report has been published

We received the Crystal Mortar Awards in all 7 categories at the 11th International Drug Chemistry Conference organized by the Turkish Chemists Society.

The 2021 Sustainability Report has been published.

We are proud to be the pharmaceutical company that allocates the highest share of total turnover to R&D in 2021.

DEVA realized a joint project with Turkish Red Crescent, one of the world's most respected institutions in the field of humanitarian aid and with whom their mission largely overlaps, on the occasion of the 150th anniversary of the latter. In addition to various events and activities, many prominent artists contributed in the celebration of this 150th anniversary by designing a collection with Hilal-i Ahmer. The Hilal-i Ahmer collection will be on display in Kanyon until the end of May. The collection will continue to be exhibited at different locations in Istanbul, as well as in Brussels and Geneva.  This succinct project has in its core the human beings and benevolence, and by bringing together corporations and art, it aims to contribute in raising awareness about social responsibility and humanitarian aid.
 
Hilal-i Ahmer: Turkish Red Crescent in Ottoman Turkish

DEVA was awarded with very meaningful prize for the support it has provided to the Hilal-i Ahmer Collection prepared on the occasion of the 150th anniversary of Turkish Red Crescent. Awards were presented to the donors of Turkish Red Crescent during the ceremony held at Istanbul Lütfi Kırdar International Congress and Exhibition Palace. The ceremony was hosted by the President of Turkish Red Crescent Dr. Kerem Kınık, under the auspices of the Presidency of the Republic of Turkey. The Minister of Health Dr. Fahrettin Koca presented the award to DEVA’s Chairman and CEO Philip Haas.

Philipp Haas made the following comments about the project: "We are very pleased to carry out projects with Turkish Red Crescent, one of the world’s most respected organizations in the field of humanitarian aid. We have been carrying out cooperation projects with Turkish Red Crescent on many issues such as medication assistance and blood donation, where our missions largely overlap.  We are happy to support Turkish Red Crescent on their 150th anniversary by taking part in the "Hilal-i Ahmer Collection" Project. We believe that this meaningful project which has in its core the human beings and benevolence, will contribute to raising awareness on social responsibility and humanitarian aid by bringing together corporations and art."

CPhI Middle East & Africa, the regional branch of the CPhI-Pharmaceuticals and Pharmaceuticals Components Fair, which holds the most prestigious meetings of the pharmaceutical industry worldwide, brought together the largest pharmaceutical companies in the Middle East and Africa on September 16-18 in Abu Dhabi. Moving rapidly towards becoming a company on a global scale, DEVA participated in CPhI MEA with a booth in 2019. DEVA International Markets and Business Development departments held meetings with business partners from around the world.

More than 4,900 health professionals visited the fair, where more than 300 companies participated, bringing together local, regional and international professionals and creating very important opportunities for the participants and visitors.

The national athlete Şahika Ercümen, sponsored by DEVA broke a new world record in her dive without fins in the Gilindire Cave and passed the 100 meters limit in a single breath of air.

Diving for a record attempt, and supported by the Ministry of Industry and Technology, the Ministry of Youth and Sports and the Çukurova Development Agency, Ercümen became the new holder of the world record which was at the limit of 90 meters, by exceeding 100 meters in a single breath of air without fins in icy water surrounded by remains from the glacial period.

Ercümen, who made it to the Guinness Book of Records, dedicated her record to Mehmetçik, the Turkish soldiers.

The world's largest and most comprehensive pharmaceutical fair, CPhI Worldwide, was held in Frankfurt on November 5-7 this year. More than 45,000 health professionals visited the fair, attended by 2,500 companies from more than 165 countries.

DEVA, whose main activity is the production and marketing of human medicinal products and pharmaceutical raw materials, as well as the production of veterinary medicines, cologne and medical bulbs, participated in CPhI Worldwide.

DEVA' senior management, international marketing, purchasing and business development departments held meetings with business partners from all over the world in this fair, which brings together suppliers and manufacturers of pharmaceuticals, and attracts visitors on a global scale who are willing to follow the developments in raw materials, machinery, packaging solutions, contract services in a cost competitive manner. DEVA was one of the most popular companies with its wide range of products and production capacity.

Believing that access to healthy living is everyone's right, DEVA is fast moving towards becoming a company on a global scale.

We are proud to be the local pharmaceutical company that allocates the highest share with 7% of total turnover in R&D.

Turkish Time, R&D Research, 2018

The BioTürkiye Congress, organized by IVEK Foundation for the development of the Turkish medical and pharmaceutical biotechnology ecosystem, took place on 5-7 March at the Ottoman Archives Complex. All stakeholders in the field of medical and pharmaceutical biotechnology came together to talk about the theme of “Biotechnology Ecosystem” at the congress in which Deva was the main sponsor. Problems were discussed by universities, industry, public and non-governmental organizations, and solution proposals were discussed.

Deputy President of the Republic of Turkey Mr. Fuat Oktay and Health Minister Mr. Fahrettin Koca also participated and delivered speeches in the Bio Türkiye Award Ceremony, which took place on the closing day of the congress. The main messages of the meeting consisted of the importance of establishing a consensus about the development, production, and marketing efforts for pharmaceuticals within the country and internationally.

Deputy President of the Republic of Turkey Mr. Fuat Oktay attended the award ceremony and presented the plaque on behalf of DEVA to Mr. Doğan Varınlıoğlu the Deputy General Manager, Turkey and International Markets.

TÜBİTAK (Scientific and Technological Research Council of Turkey) has introduced the Industrial PhD Program to meet the industry’s increasing demand for qualified people with a PhD degree based on a collaborative approach that involves the universities and industry. Under this program, also joined in by DEVA, collaborative projects between 33 universities and 77 companies qualified to receive incentives. This program offers grants to PhD students and recruitment support for private companies and aims to meet the need for highly qualified staff using a collaborative approach that involves the real sector and academic world. Mr Mustafa Varank, Minister for Industry and Technology, presented a certificate of attendance to Ms Esen Bellur Atıcı, R&D API Manager at DEVA.

CPhI Worldwide, world’s largest and most extensive pharmaceutical exhibition, was held on 9 - 11 September in Madrid. The show, attended by over 2,500 companies, was visited by more than 45,000 HCPs from almost 150 countries. With a primary focus on the manufacture and marketing of medicines for human use along with production of veterinary products and pharmaceutical ingredients, DEVA attended CPhI Worldwide 2018.
 
The exhibition attracts visitors involved in the production of ingredients, machines, packaging solutions, and contract services along with players who aim to be competitive in their local markets and brings together global suppliers and drug manufacturers. This provided DEVA’s leaders as well as representatives from the international markets, purchasing, and business development departments an opportunity to meet with business partners from all over the world. With an extensive product portfolio and a high production capacity, DEVA was one of the highlights of the exhibition. 
 
Committed to promote a healthy life for everybody, DEVA takes major strides in becoming a global company.    

After entering the ophthalmology market with the launch of the first local topical cyclosporin in 2014, DEVA strengthened its presence by introducing almost 20 different products in a very short period of time. After building trust among ophthalmologist, DEVA is now bringing in a brand-new project.

The launch meeting of the photography contest titled "We see and appreciate the meaning of life...", which is open to ophthalmologists and focuses on objects and compositions that resemble the human eye, was held last week under the moderation of the renowned photographer Nihat Odabaşı. A jury composed of key opinion leaders in the field of ophthalmology met with Nihat Odabaşı to set up a roadmap for this project.

Before the start of the meeting, the doctors had the opportunity to visit DEVA's EU GMP and US FDA-approved production facilities and receive information about the manufacturing processes.

DEVA ranks 207 among Turkey’s Top 500 industrial organizations We manufacture for our nation, and take major strides to become a global company... Adding health to life...

To meet the increasing storage requirements that are brought about by its expanding product portfolio and growing manufacturing activities, the construction of a logistics center of DEVA got underway in Çerkezköy beginning of this year. The facility was recently completed and passed the audit of the Turkish MoH. The facility is built on an 8,600 m2 area with a capacity of 25,200 pallets and serves as a distribution hub for any product manufactured for the domestic and international markets, reaching a total daily volume of up to 2 million units a day. The facility also boasts about being the largest logistics center among all pharma companies based in Turkey. 

DEVA continues to manufacture for a healthy future …    

While taking major strides to become a global company, DEVA also works to make its high-quality and innovative products accessible to people all around the world.

Devatis, an affiliate responsible for part of our international operations, was recently registered as a pharmaceutical company in Switzerland after Germany. This development not only highlights the trust it inspires as a commercial brand, Devatis will also be able to continue its import and and export activities and file for new licenses at the authorities.